← Back to Search

Anticoagulant

Enoxaparin for Deep Vein Thrombosis

Phase 4
Waitlist Available
Led By Hassan Mir, MD
Research Sponsored by Florida Orthopaedic Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

This trial is testing if a pill is better than a shot for people with broken bones. The pill is easier to take, so people may be more likely to stick with it.

Eligible Conditions
  • Deep Vein Thrombosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
adherence to medication regimen
patient satisfaction with treatment regimen
Secondary outcome measures
Number of participants with a bleeding event
Number of participants with a clotting event
treatment cost

Trial Design

2Treatment groups
Active Control
Group I: EnoxaparinActive Control1 Intervention
enoxaparin injectable, 40 milligram subcutaneous injection daily for 20 days
Group II: RivaroxabanActive Control1 Intervention
rivaroxaban oral 10 milligram tablet daily for 20 days

Find a Location

Who is running the clinical trial?

Orthopaedic Trauma AssociationOTHER
32 Previous Clinical Trials
4,888 Total Patients Enrolled
Florida Orthopaedic InstituteLead Sponsor
8 Previous Clinical Trials
347 Total Patients Enrolled
Hassan Mir, MDPrincipal InvestigatorFlorida Orthopaedic Institute
4 Previous Clinical Trials
762 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban
Barbara Steverson 2020. "Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04169269.
All > Xarelto
~24 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top